Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2012-12

AUTHORS

Thomas Yau, Hilda Wong, Pierre Chan, T. J. Yao, R. Pang, T. T. Cheung, S. T. Fan, Ronnie T. Poon

ABSTRACT

BACKGROUND: The combination of bevacizumab (B) and erlotinib (E) has shown promising clinical outcomes as the first-line treatment of advanced HCC patients. We aimed to evaluate the efficacy and safety of using combination of B + E in treating advanced HCC patients who had failed prior sorafenib treatment. METHODS: Eligible advanced HCC patients with documented radiological evidence of disease progression with sorafenib treatment were recruited. All patients received bevacizumab(B) at 10 mg/kg every 2 weeks with erlotinib(E) at 150 mg daily for a maximum of 6 cycles. Response assessments using both RECIST and modified RECIST criteria were performed after every 6 weeks. The primary endpoint was clinical benefit (CB) rate and a Simon two-stage design was employed. RESULTS: The trial was halted in the first stage according to the pre-set statistical criteria with 10 patients recruited. The median age was 47 years (range, 28-61) and all patients were in ECOG performance status 1. Eighty percent of patients were chronic hepatitis B carriers and all patients had Child A cirrhosis. Among these 10 patients, none of the enrolled patients achieved response or stable disease. The median time-to-progression was 1.81 months (95 % confidence interval [C.I.], 1.08-1.74 months) and overall survival was 4.37 months (95 % C.I., 1.08-11.66 months). Rash (70 %), diarrhea (50 %) and malaise (40 %) were the most commonly encountered toxicities. CONCLUSION: The combination of B + E was well tolerated but had no activity in an unselected sorafenib-refractory advanced HCC population. Condensed abstract The combination of bevacizumab and erlotinib had no clinical activity in sorafenib-refractory HCC population. More... »

PAGES

2384-2390

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10637-012-9808-8

DOI

http://dx.doi.org/10.1007/s10637-012-9808-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1000539631

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22402942


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bevacizumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Hepatocellular", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Neoplasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Erlotinib Hydrochloride", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kaplan-Meier Estimate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Niacinamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phenylurea Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quinazolines", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Queen Mary Hospital", 
          "id": "https://www.grid.ac/institutes/grid.415550.0", 
          "name": [
            "Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Room 211B, 2/F New Clinical Building, 102 Pokfulam Road, Hong Kong, China", 
            "Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yau", 
        "givenName": "Thomas", 
        "id": "sg:person.011372244704.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011372244704.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen Mary Hospital", 
          "id": "https://www.grid.ac/institutes/grid.415550.0", 
          "name": [
            "Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wong", 
        "givenName": "Hilda", 
        "id": "sg:person.01215754544.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01215754544.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen Mary Hospital", 
          "id": "https://www.grid.ac/institutes/grid.415550.0", 
          "name": [
            "Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chan", 
        "givenName": "Pierre", 
        "id": "sg:person.07742761162.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07742761162.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Clinical Trials Centre, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yao", 
        "givenName": "T. J.", 
        "id": "sg:person.015660107072.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015660107072.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Room 211B, 2/F New Clinical Building, 102 Pokfulam Road, Hong Kong, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pang", 
        "givenName": "R.", 
        "id": "sg:person.013420356062.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013420356062.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Room 211B, 2/F New Clinical Building, 102 Pokfulam Road, Hong Kong, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cheung", 
        "givenName": "T. T.", 
        "id": "sg:person.014131650672.94", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014131650672.94"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Room 211B, 2/F New Clinical Building, 102 Pokfulam Road, Hong Kong, China", 
            "State Key Laboratory of Liver Diseases, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fan", 
        "givenName": "S. T.", 
        "id": "sg:person.01111046126.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01111046126.83"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Room 211B, 2/F New Clinical Building, 102 Pokfulam Road, Hong Kong, China", 
            "State Key Laboratory of Liver Diseases, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Poon", 
        "givenName": "Ronnie T.", 
        "id": "sg:person.07501676632.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07501676632.96"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1200/jco.2005.04.9130", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000005363"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(09)70002-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006353914"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0168-8278(97)80323-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008206545"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.26556", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012984986"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00000658-200204000-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013218119"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00000658-200204000-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013218119"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc2442", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013847179", 
          "https://doi.org/10.1038/nrc2442"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-04-1443", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014291431"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.22886", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016156123"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(08)70285-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018829845"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ccr.2009.01.027", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020649367"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-08-0141", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026859911"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.18.3301", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028912825"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-010-1257-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031051488", 
          "https://doi.org/10.1007/s00280-010-1257-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-010-1257-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031051488", 
          "https://doi.org/10.1007/s00280-010-1257-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ajh.21745", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032123617"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ajh.21745", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032123617"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/92.3.205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032301848"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/0284186x.2011.619568", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035031420"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0046-8177(97)90179-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036897106"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.14.696", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038163117"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.15.9947", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039038559"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12156-011-0082-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046125571", 
          "https://doi.org/10.1007/s12156-011-0082-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/djn134", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050426018"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa0708857", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053513212"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3892/ijo.14.3.453", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071510959"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3892/or.8.4.903", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071536481"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4161/cbt.11.8.14889", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072292445"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4251/wjgo.v2.i9.348", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072401926"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1076633385", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083175627", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-12", 
    "datePublishedReg": "2012-12-01", 
    "description": "BACKGROUND: The combination of bevacizumab (B) and erlotinib (E) has shown promising clinical outcomes as the first-line treatment of advanced HCC patients. We aimed to evaluate the efficacy and safety of using combination of B\u2009+\u2009E in treating advanced HCC patients who had failed prior sorafenib treatment.\nMETHODS: Eligible advanced HCC patients with documented radiological evidence of disease progression with sorafenib treatment were recruited. All patients received bevacizumab(B) at 10 mg/kg every 2 weeks with erlotinib(E) at 150 mg daily for a maximum of 6 cycles. Response assessments using both RECIST and modified RECIST criteria were performed after every 6 weeks. The primary endpoint was clinical benefit (CB) rate and a Simon two-stage design was employed.\nRESULTS: The trial was halted in the first stage according to the pre-set statistical criteria with 10 patients recruited. The median age was 47 years (range, 28-61) and all patients were in ECOG performance status 1. Eighty percent of patients were chronic hepatitis B carriers and all patients had Child A cirrhosis. Among these 10 patients, none of the enrolled patients achieved response or stable disease. The median time-to-progression was 1.81 months (95 % confidence interval [C.I.], 1.08-1.74 months) and overall survival was 4.37 months (95 % C.I., 1.08-11.66 months). Rash (70 %), diarrhea (50 %) and malaise (40 %) were the most commonly encountered toxicities.\nCONCLUSION: The combination of B\u2009+\u2009E was well tolerated but had no activity in an unselected sorafenib-refractory advanced HCC population. Condensed abstract The combination of bevacizumab and erlotinib had no clinical activity in sorafenib-refractory HCC population.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10637-012-9808-8", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "30"
      }
    ], 
    "name": "Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease", 
    "pagination": "2384-2390", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "0291706f876e53bf3ed1beb7a3b0d7960e475262241ec9f6ca3337cb05089a37"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22402942"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309330"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10637-012-9808-8"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1000539631"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10637-012-9808-8", 
      "https://app.dimensions.ai/details/publication/pub.1000539631"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T22:38", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8690_00000545.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3484314/"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-012-9808-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-012-9808-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-012-9808-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-012-9808-8'


 

This table displays all metadata directly associated to this object as RDF triples.

280 TRIPLES      21 PREDICATES      73 URIs      37 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10637-012-9808-8 schema:about N226fdf170e044dd382e1c057076cb512
2 N28c51eee6bae4a99984ccd2ea9a888ee
3 N2d604d51305e43abb065f2de820a6774
4 N3714397c768d44cb9729c9e2b055baf9
5 N40cbcabf4a3a49d48e4cabf455a4bb80
6 N5055689befe0421096fc6dcb61395d85
7 N50d03951d5ba48b9acd9d229239a80fc
8 N5c6ed4b0d83141bb89c52765a2fcc2f1
9 N5d4b44e29bbf4e9c847ba5446a255091
10 N61abf6ede2f740019f2f9af49a1fe684
11 Na9f15bcded9e4271bac322367eb76cb1
12 Nae29b7211a5742cd838c690c0fa65f83
13 Nba1ca3577994481dbbbb8a7c936b72bb
14 Nc4a5b6ebd74947798ad4a1fe9c524b1f
15 Ned90a8f5bc4942819e6807ded1ea5e70
16 Nf2ab23745fa444478ef0af5fad0a14f3
17 anzsrc-for:11
18 anzsrc-for:1103
19 schema:author N3da1a655b17541e29eb0187a66c87170
20 schema:citation sg:pub.10.1007/s00280-010-1257-5
21 sg:pub.10.1007/s12156-011-0082-3
22 sg:pub.10.1038/nrc2442
23 https://app.dimensions.ai/details/publication/pub.1076633385
24 https://app.dimensions.ai/details/publication/pub.1083175627
25 https://doi.org/10.1002/ajh.21745
26 https://doi.org/10.1002/cncr.22886
27 https://doi.org/10.1002/cncr.26556
28 https://doi.org/10.1016/j.ccr.2009.01.027
29 https://doi.org/10.1016/s0046-8177(97)90179-9
30 https://doi.org/10.1016/s0168-8278(97)80323-6
31 https://doi.org/10.1016/s1470-2045(08)70285-7
32 https://doi.org/10.1016/s1470-2045(09)70002-6
33 https://doi.org/10.1056/nejmoa0708857
34 https://doi.org/10.1093/jnci/92.3.205
35 https://doi.org/10.1093/jnci/djn134
36 https://doi.org/10.1097/00000658-200204000-00004
37 https://doi.org/10.1158/0008-5472.can-04-1443
38 https://doi.org/10.1158/1078-0432.ccr-08-0141
39 https://doi.org/10.1200/jco.2005.04.9130
40 https://doi.org/10.1200/jco.2005.14.696
41 https://doi.org/10.1200/jco.2007.15.9947
42 https://doi.org/10.1200/jco.2008.18.3301
43 https://doi.org/10.3109/0284186x.2011.619568
44 https://doi.org/10.3892/ijo.14.3.453
45 https://doi.org/10.3892/or.8.4.903
46 https://doi.org/10.4161/cbt.11.8.14889
47 https://doi.org/10.4251/wjgo.v2.i9.348
48 schema:datePublished 2012-12
49 schema:datePublishedReg 2012-12-01
50 schema:description BACKGROUND: The combination of bevacizumab (B) and erlotinib (E) has shown promising clinical outcomes as the first-line treatment of advanced HCC patients. We aimed to evaluate the efficacy and safety of using combination of B + E in treating advanced HCC patients who had failed prior sorafenib treatment. METHODS: Eligible advanced HCC patients with documented radiological evidence of disease progression with sorafenib treatment were recruited. All patients received bevacizumab(B) at 10 mg/kg every 2 weeks with erlotinib(E) at 150 mg daily for a maximum of 6 cycles. Response assessments using both RECIST and modified RECIST criteria were performed after every 6 weeks. The primary endpoint was clinical benefit (CB) rate and a Simon two-stage design was employed. RESULTS: The trial was halted in the first stage according to the pre-set statistical criteria with 10 patients recruited. The median age was 47 years (range, 28-61) and all patients were in ECOG performance status 1. Eighty percent of patients were chronic hepatitis B carriers and all patients had Child A cirrhosis. Among these 10 patients, none of the enrolled patients achieved response or stable disease. The median time-to-progression was 1.81 months (95 % confidence interval [C.I.], 1.08-1.74 months) and overall survival was 4.37 months (95 % C.I., 1.08-11.66 months). Rash (70 %), diarrhea (50 %) and malaise (40 %) were the most commonly encountered toxicities. CONCLUSION: The combination of B + E was well tolerated but had no activity in an unselected sorafenib-refractory advanced HCC population. Condensed abstract The combination of bevacizumab and erlotinib had no clinical activity in sorafenib-refractory HCC population.
51 schema:genre research_article
52 schema:inLanguage en
53 schema:isAccessibleForFree true
54 schema:isPartOf N8ffd3be740514542b5f53d6b89a2f9ee
55 Nd525f94e2b74413d9f9600ce912480ed
56 sg:journal.1094201
57 schema:name Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease
58 schema:pagination 2384-2390
59 schema:productId N29b3188f609a4d73886918429a04c4b4
60 N408187805b224382b0b750fc05d2c16d
61 N6042b73392634e129085ef17f3ca9214
62 Nbeec4461f6b442728f2ae25bc50adb9f
63 Nda0afda1241243c0958c6eff7a2914d6
64 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000539631
65 https://doi.org/10.1007/s10637-012-9808-8
66 schema:sdDatePublished 2019-04-10T22:38
67 schema:sdLicense https://scigraph.springernature.com/explorer/license/
68 schema:sdPublisher N1ff88b1a0ca9411abed24199035121d2
69 schema:url http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3484314/
70 sgo:license sg:explorer/license/
71 sgo:sdDataset articles
72 rdf:type schema:ScholarlyArticle
73 N1ff88b1a0ca9411abed24199035121d2 schema:name Springer Nature - SN SciGraph project
74 rdf:type schema:Organization
75 N226fdf170e044dd382e1c057076cb512 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Niacinamide
77 rdf:type schema:DefinedTerm
78 N28c51eee6bae4a99984ccd2ea9a888ee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Middle Aged
80 rdf:type schema:DefinedTerm
81 N29078599fc1d4c5bad94fa6656c157ce rdf:first sg:person.07501676632.96
82 rdf:rest rdf:nil
83 N29b3188f609a4d73886918429a04c4b4 schema:name dimensions_id
84 schema:value pub.1000539631
85 rdf:type schema:PropertyValue
86 N2d604d51305e43abb065f2de820a6774 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Phenylurea Compounds
88 rdf:type schema:DefinedTerm
89 N30ce9d0e5e5140d1aa908cc472839c77 schema:name Clinical Trials Centre, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China
90 rdf:type schema:Organization
91 N3714397c768d44cb9729c9e2b055baf9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Female
93 rdf:type schema:DefinedTerm
94 N3ce05cc452af470c8d6ebeaa9ca58176 rdf:first sg:person.015660107072.06
95 rdf:rest N4ff5192b286b4a66b9858678e9e81662
96 N3da1a655b17541e29eb0187a66c87170 rdf:first sg:person.011372244704.72
97 rdf:rest Nd6c6d55d8f2846e9bb9be41aafe98cac
98 N408187805b224382b0b750fc05d2c16d schema:name pubmed_id
99 schema:value 22402942
100 rdf:type schema:PropertyValue
101 N40cbcabf4a3a49d48e4cabf455a4bb80 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Adult
103 rdf:type schema:DefinedTerm
104 N4ff5192b286b4a66b9858678e9e81662 rdf:first sg:person.013420356062.81
105 rdf:rest Nd115d443624f4aa095c29188236530e0
106 N5055689befe0421096fc6dcb61395d85 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Quinazolines
108 rdf:type schema:DefinedTerm
109 N50d03951d5ba48b9acd9d229239a80fc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Bevacizumab
111 rdf:type schema:DefinedTerm
112 N5c6ed4b0d83141bb89c52765a2fcc2f1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Carcinoma, Hepatocellular
114 rdf:type schema:DefinedTerm
115 N5d4b44e29bbf4e9c847ba5446a255091 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Humans
117 rdf:type schema:DefinedTerm
118 N6042b73392634e129085ef17f3ca9214 schema:name doi
119 schema:value 10.1007/s10637-012-9808-8
120 rdf:type schema:PropertyValue
121 N61abf6ede2f740019f2f9af49a1fe684 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Antibodies, Monoclonal, Humanized
123 rdf:type schema:DefinedTerm
124 N8d14492b4d3f43559ce6ac7dfa465327 schema:name Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Room 211B, 2/F New Clinical Building, 102 Pokfulam Road, Hong Kong, China
125 rdf:type schema:Organization
126 N8ffd3be740514542b5f53d6b89a2f9ee schema:volumeNumber 30
127 rdf:type schema:PublicationVolume
128 Na9f15bcded9e4271bac322367eb76cb1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Drug Resistance, Neoplasm
130 rdf:type schema:DefinedTerm
131 Nae29b7211a5742cd838c690c0fa65f83 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Kaplan-Meier Estimate
133 rdf:type schema:DefinedTerm
134 Nba1ca3577994481dbbbb8a7c936b72bb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Antineoplastic Combined Chemotherapy Protocols
136 rdf:type schema:DefinedTerm
137 Nbeec4461f6b442728f2ae25bc50adb9f schema:name nlm_unique_id
138 schema:value 8309330
139 rdf:type schema:PropertyValue
140 Nc115d780a18f4548987218c14ee6109c schema:name Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Room 211B, 2/F New Clinical Building, 102 Pokfulam Road, Hong Kong, China
141 rdf:type schema:Organization
142 Nc147bec1834943b198ab255b14a0bc7f rdf:first sg:person.01111046126.83
143 rdf:rest N29078599fc1d4c5bad94fa6656c157ce
144 Nc4a5b6ebd74947798ad4a1fe9c524b1f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Liver Neoplasms
146 rdf:type schema:DefinedTerm
147 Nc8d4ceae2dee470ca6a4ce402c1f56d2 schema:name Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Room 211B, 2/F New Clinical Building, 102 Pokfulam Road, Hong Kong, China
148 State Key Laboratory of Liver Diseases, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China
149 rdf:type schema:Organization
150 Nd115d443624f4aa095c29188236530e0 rdf:first sg:person.014131650672.94
151 rdf:rest Nc147bec1834943b198ab255b14a0bc7f
152 Nd525f94e2b74413d9f9600ce912480ed schema:issueNumber 6
153 rdf:type schema:PublicationIssue
154 Nd6c6d55d8f2846e9bb9be41aafe98cac rdf:first sg:person.01215754544.31
155 rdf:rest Ndf9d0e53ca9e4dd58f94f3ded153af17
156 Nda0afda1241243c0958c6eff7a2914d6 schema:name readcube_id
157 schema:value 0291706f876e53bf3ed1beb7a3b0d7960e475262241ec9f6ca3337cb05089a37
158 rdf:type schema:PropertyValue
159 Ndf9d0e53ca9e4dd58f94f3ded153af17 rdf:first sg:person.07742761162.25
160 rdf:rest N3ce05cc452af470c8d6ebeaa9ca58176
161 Ned90a8f5bc4942819e6807ded1ea5e70 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Erlotinib Hydrochloride
163 rdf:type schema:DefinedTerm
164 Nf2ab23745fa444478ef0af5fad0a14f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Male
166 rdf:type schema:DefinedTerm
167 Nfd1ac795994b43e295126a9aaa8f320b schema:name Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Room 211B, 2/F New Clinical Building, 102 Pokfulam Road, Hong Kong, China
168 State Key Laboratory of Liver Diseases, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China
169 rdf:type schema:Organization
170 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
171 schema:name Medical and Health Sciences
172 rdf:type schema:DefinedTerm
173 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
174 schema:name Clinical Sciences
175 rdf:type schema:DefinedTerm
176 sg:journal.1094201 schema:issn 0167-6997
177 1573-0646
178 schema:name Investigational New Drugs
179 rdf:type schema:Periodical
180 sg:person.01111046126.83 schema:affiliation Nfd1ac795994b43e295126a9aaa8f320b
181 schema:familyName Fan
182 schema:givenName S. T.
183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01111046126.83
184 rdf:type schema:Person
185 sg:person.011372244704.72 schema:affiliation https://www.grid.ac/institutes/grid.415550.0
186 schema:familyName Yau
187 schema:givenName Thomas
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011372244704.72
189 rdf:type schema:Person
190 sg:person.01215754544.31 schema:affiliation https://www.grid.ac/institutes/grid.415550.0
191 schema:familyName Wong
192 schema:givenName Hilda
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01215754544.31
194 rdf:type schema:Person
195 sg:person.013420356062.81 schema:affiliation Nc115d780a18f4548987218c14ee6109c
196 schema:familyName Pang
197 schema:givenName R.
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013420356062.81
199 rdf:type schema:Person
200 sg:person.014131650672.94 schema:affiliation N8d14492b4d3f43559ce6ac7dfa465327
201 schema:familyName Cheung
202 schema:givenName T. T.
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014131650672.94
204 rdf:type schema:Person
205 sg:person.015660107072.06 schema:affiliation N30ce9d0e5e5140d1aa908cc472839c77
206 schema:familyName Yao
207 schema:givenName T. J.
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015660107072.06
209 rdf:type schema:Person
210 sg:person.07501676632.96 schema:affiliation Nc8d4ceae2dee470ca6a4ce402c1f56d2
211 schema:familyName Poon
212 schema:givenName Ronnie T.
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07501676632.96
214 rdf:type schema:Person
215 sg:person.07742761162.25 schema:affiliation https://www.grid.ac/institutes/grid.415550.0
216 schema:familyName Chan
217 schema:givenName Pierre
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07742761162.25
219 rdf:type schema:Person
220 sg:pub.10.1007/s00280-010-1257-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031051488
221 https://doi.org/10.1007/s00280-010-1257-5
222 rdf:type schema:CreativeWork
223 sg:pub.10.1007/s12156-011-0082-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046125571
224 https://doi.org/10.1007/s12156-011-0082-3
225 rdf:type schema:CreativeWork
226 sg:pub.10.1038/nrc2442 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013847179
227 https://doi.org/10.1038/nrc2442
228 rdf:type schema:CreativeWork
229 https://app.dimensions.ai/details/publication/pub.1076633385 schema:CreativeWork
230 https://app.dimensions.ai/details/publication/pub.1083175627 schema:CreativeWork
231 https://doi.org/10.1002/ajh.21745 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032123617
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1002/cncr.22886 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016156123
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1002/cncr.26556 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012984986
236 rdf:type schema:CreativeWork
237 https://doi.org/10.1016/j.ccr.2009.01.027 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020649367
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1016/s0046-8177(97)90179-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036897106
240 rdf:type schema:CreativeWork
241 https://doi.org/10.1016/s0168-8278(97)80323-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008206545
242 rdf:type schema:CreativeWork
243 https://doi.org/10.1016/s1470-2045(08)70285-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018829845
244 rdf:type schema:CreativeWork
245 https://doi.org/10.1016/s1470-2045(09)70002-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006353914
246 rdf:type schema:CreativeWork
247 https://doi.org/10.1056/nejmoa0708857 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053513212
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1093/jnci/92.3.205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032301848
250 rdf:type schema:CreativeWork
251 https://doi.org/10.1093/jnci/djn134 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050426018
252 rdf:type schema:CreativeWork
253 https://doi.org/10.1097/00000658-200204000-00004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013218119
254 rdf:type schema:CreativeWork
255 https://doi.org/10.1158/0008-5472.can-04-1443 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014291431
256 rdf:type schema:CreativeWork
257 https://doi.org/10.1158/1078-0432.ccr-08-0141 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026859911
258 rdf:type schema:CreativeWork
259 https://doi.org/10.1200/jco.2005.04.9130 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000005363
260 rdf:type schema:CreativeWork
261 https://doi.org/10.1200/jco.2005.14.696 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038163117
262 rdf:type schema:CreativeWork
263 https://doi.org/10.1200/jco.2007.15.9947 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039038559
264 rdf:type schema:CreativeWork
265 https://doi.org/10.1200/jco.2008.18.3301 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028912825
266 rdf:type schema:CreativeWork
267 https://doi.org/10.3109/0284186x.2011.619568 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035031420
268 rdf:type schema:CreativeWork
269 https://doi.org/10.3892/ijo.14.3.453 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071510959
270 rdf:type schema:CreativeWork
271 https://doi.org/10.3892/or.8.4.903 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071536481
272 rdf:type schema:CreativeWork
273 https://doi.org/10.4161/cbt.11.8.14889 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072292445
274 rdf:type schema:CreativeWork
275 https://doi.org/10.4251/wjgo.v2.i9.348 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072401926
276 rdf:type schema:CreativeWork
277 https://www.grid.ac/institutes/grid.415550.0 schema:alternateName Queen Mary Hospital
278 schema:name Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China
279 Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Room 211B, 2/F New Clinical Building, 102 Pokfulam Road, Hong Kong, China
280 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...